ACHV · Achieve Life Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | $5.32M | $6.71M | $7.10M | - | $7.61M | $5.11M | $2.80M | - |
| SG&A | - | - | $9.37M | $5.86M | $5.80M | - | $4.86M | $3.32M | $3.18M | - |
| Total Operating Expenses | $10.46M | - | $14.69M | $12.56M | $12.89M | - | $12.47M | $8.43M | $5.98M | - |
| D&A | $57.0K | - | - | - | $62.0K | - | - | - | $57.0K | - |
| Operating Income | - | - | - | - | - | - | - | - | - | - |
| Interest Expense | $274.0K | - | $366.0K | $804.0K | $813.0K | - | $366.0K | $804.0K | $813.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($10.17M) | - | ($14.44M) | ($12.72M) | ($12.83M) | - | ($12.51M) | ($8.46M) | ($6.49M) | - |
| EPS - Basic | ($0.19) | - | ($0.28) | ($0.37) | ($0.37) | - | ($0.36) | ($0.25) | ($0.26) | - |
| EPS - Diluted | ($0.19) | - | ($0.28) | ($0.37) | ($0.37) | - | ($0.36) | ($0.25) | ($0.26) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.08M | $20.93M | $31.93M | $51.87M | $13.02M | $12.75M | $9.54M | $14.76M | $66.40M | $15.55M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | $1.94M | $1.22M | $1.66M | $1.95M | $1.01M | $550.0K | $373.0K | $618.0K |
| Current Assets | $31.06M | $39.89M | $50.05M | $56.90M | $25.00M | $36.47M | $45.53M | $62.52M | $67.71M | $16.98M |
| Total Assets | $33.10M | $41.79M | $52.04M | $58.94M | $27.36M | $38.63M | $47.92M | $64.79M | $70.03M | $19.37M |
| Current Liabilities | $11.83M | $9.08M | $9.73M | $8.57M | $7.13M | $6.68M | $6.72M | $13.70M | $20.57M | $20.81M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $22.43M | $20.27M | $18.43M | $17.27M | $17.08M | $17.73M | $16.54M | $22.51M | $20.57M | $20.82M |
| Stockholders' Equity | $10.68M | $21.52M | $33.62M | $41.67M | $10.28M | $20.90M | $31.38M | $42.28M | $49.46M | ($1.45M) |
| Retained Earnings | ($270.39M) | ($260.23M) | ($245.56M) | ($231.12M) | ($218.41M) | ($205.58M) | ($193.22M) | ($180.71M) | ($172.25M) | ($165.75M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.93M) | - | - | - | ($11.09M) | - | - | - | ($5.29M) | - |
| Investing Cash Flow | $14.28M | - | - | - | $11.35M | - | - | - | - | - |
| Financing Cash Flow | $21.0K | - | - | - | - | - | - | - | $56.11M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -30.7% | - | -27.7% | -21.6% | -46.9% | - | -26.1% | -13.1% | -9.3% | - |
| Return on equity | -95.2% | - | -43.0% | -30.5% | -124.8% | - | -39.9% | -20.0% | -13.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 |
| Quick ratio | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 |
| Cash ratio | 2.37 | 2.30 | 3.28 | 6.05 | 1.83 | 1.91 | 1.42 | 1.08 | 3.23 | 0.75 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.10 | 1.94 | 1.55 | 1.41 | 2.66 | 1.85 | 1.53 | 1.53 | 1.42 | -13.38 |
| Liabilities / Assets | 0.68 | 0.49 | 0.35 | 0.29 | 0.62 | 0.46 | 0.35 | 0.35 | 0.29 | 1.07 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 14.7x | - | 4.8x | 1.9x | 9.0x | - | 5.2x | 3.8x | 2.3x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | 20.7% | - | -15.4% | -50.3% | -97.5% | - | -76.0% | -2.7% | 27.8% | - |
| EPS growth (YoY) | 48.6% | - | 22.2% | -48.0% | -42.3% | - | -5.9% | 41.9% | 67.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 3.9% | 3.0% | 7.1% | -1.5% | -79.2% | - | 677.1% | 336.0% | 11063.9% | - |
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing ACHIEVE LIFE SCIENCES against the 5 most active filers in the same SIC group.